Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ: FBLG )

3.180 +0.160 (+5.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about FibroBiologics, Inc. - Common Stock

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs 
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Engages Southern Star Research as CRO in Australia
Southern Star Research will provide CRO services for FibroBiologics in Australia 
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Files 2024 Second Quarter Report
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at JonesTrading Healthcare Summit 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Set to Join Russell 2000® Index
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces 2024 Annual Meeting of Stockholders
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Files 2024 First Quarter Report
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at the BIO International Convention 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
Next-generation cell therapies to target chronic diseases 
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics (NASDAQ: FBLG) Shares Jump 88% After Announcing Preclinical Data During Presentation at 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
FibroBiologics (NASDAQ: FBLG) shares caught a notable bid during trading on Tuesday, February 13, 2024. The clinical-stage biotech company saw 
Via Spotlight Growth
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.